AbstractObjectivesThis study assesses satisfaction with iron chelation therapy (ICT) based on a reliable and valid instrument, and explores the relationship between satisfaction and adherence to ICT.MethodsPatients in the USA and UK completed a new “Satisfaction with ICT” (SICT) instrument consisting of 28 items, three pertaining to adherence. Simple and multivariate regression analyses assessed the relationship between satisfaction with different aspects of ICT and adherence.ResultsFirst assessments of the SICT instrument indicate its validity and reliability. Recommended thresholds for internal consistency, convergent validity, discriminant validity, and floor and ceiling effects were met. A number of variables were identified in the simp...
Introduction: Deferasirox, an oral iron chelator has been proved to be very safe and effective in be...
Background and Aim: With the introduction of long term subcutaneous administration of Deferoxamine t...
grantor: University of TorontoPatients with transfusional dependent ß-thalassemia require ...
AbstractObjectivesThis study assesses satisfaction with iron chelation therapy (ICT) based on a reli...
Background: Thalassemia is a chronic disease requiring lifelong treatment. The adherence to regular ...
Abstract Background Compliance, palatability, gastrointestinal (GI) symptom, and treatment satisfact...
Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patie...
Background: Transfusion-related iron overload is a complication of chronic transfusion therapy in p...
BACKGROUND: Adherence to long-term chelation therapy in transfusion-dependent patients is critical t...
Review question We wanted to determine if there are any interventions (medication, psychological or ...
AbstractObjectiveTo investigate the utility associated with subcutaneous infusion (deferoxamine) com...
Objective: This study was conducted to identify predictors of non-adherence to iron chelation therap...
Objectives: Iron chelation treatment (ICT) in β-thalassemia major (β-TM) patients undergoing blood t...
Background: Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treat...
OBJECTIVES: In patients with myelodysplastic syndromes (MDS) with >20 transfusions and ferritin l...
Introduction: Deferasirox, an oral iron chelator has been proved to be very safe and effective in be...
Background and Aim: With the introduction of long term subcutaneous administration of Deferoxamine t...
grantor: University of TorontoPatients with transfusional dependent ß-thalassemia require ...
AbstractObjectivesThis study assesses satisfaction with iron chelation therapy (ICT) based on a reli...
Background: Thalassemia is a chronic disease requiring lifelong treatment. The adherence to regular ...
Abstract Background Compliance, palatability, gastrointestinal (GI) symptom, and treatment satisfact...
Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patie...
Background: Transfusion-related iron overload is a complication of chronic transfusion therapy in p...
BACKGROUND: Adherence to long-term chelation therapy in transfusion-dependent patients is critical t...
Review question We wanted to determine if there are any interventions (medication, psychological or ...
AbstractObjectiveTo investigate the utility associated with subcutaneous infusion (deferoxamine) com...
Objective: This study was conducted to identify predictors of non-adherence to iron chelation therap...
Objectives: Iron chelation treatment (ICT) in β-thalassemia major (β-TM) patients undergoing blood t...
Background: Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treat...
OBJECTIVES: In patients with myelodysplastic syndromes (MDS) with >20 transfusions and ferritin l...
Introduction: Deferasirox, an oral iron chelator has been proved to be very safe and effective in be...
Background and Aim: With the introduction of long term subcutaneous administration of Deferoxamine t...
grantor: University of TorontoPatients with transfusional dependent ß-thalassemia require ...